Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 4, 2004, Pages 360-364

  Quiralte, Joaquín ^a   Delgado, Julio ^b   Sáenz De San Pedro, Bianca ^a   López Pascual, Esperanza ^a   Nieto, Maria Angustias ^b   Ortega, Nancy ^c   Florido, Jose Fernando ^a   Conde, José ^b  

^a Unidad de Alergia   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPYRONE; KETOPROFEN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PROPYPHENAZONE; PYRAZOLE DERIVATIVE; ROFECOXIB;

ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; EMERGENCY WARD; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INFLAMMATION; LARYNX EDEMA; MALE; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN MANIFESTATION; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; URTICARIA;

EID: 6044264974     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61395-6     Document Type: Article

References (23)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
2. MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003;52: 1265-1270.
3. Dahlen B, Szczeklik A, Murray JJ; Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance [letter]. N Engl J Med. 2001; 344:142.
4. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H. Selective cyclooxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol. 2000;106: 1201-1202.
5. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol. 2001;108:47-51.
6. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol. 2003;111:1116-1121.
7. Quiralte J, Sáenz de San Pedro B, Florido JF. Safety of selective cyclooxygenase-2 inhibitor in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol. 2002;89: 63-66.
8. Quiralte J, Blanco C, Castillo R, Ortega N, Carrillo T. Anaphylactoid reaction due to non-steroidal antiinflammatory drugs: clinical and cross-reactivity studies. Ann Allergy Asthma Immunol. 1997;78:293-296.
9. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365.
10. Quiralte J, Blanco C, Castillo R, Delgado J, Carrillo T. Intolerance to non-steroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996;98:678-685.
11. Israel E, Fischer A, Rosenberg M, et al. The pivotal role of 5-lipooxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148:1447-1451.
12. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to non-steroidal antiinflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977;60: 276-284.
13. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001; 87:177-180.
14. Quiralte J, Sánchez-García F, Torres MJ, et al. Association of HLA-DR11 with the anaphylactoid reaction caused by non-steroidal antiinflammatory drugs. J Allergy Clin Immunol. 1999; 103:685-689.
15. Berkes EA. Anaphylactic and anaphylactoid reactions to aspirin and other NSAIDs. Clin Rev Allergy Immunol. 2003;24: 137-148.
16. Himly M, Jahn-Schmid B, Pittertschatscher K, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol. 2003;111: 882-888.
17. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307-314.
18. Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol. 2002;2:307-315.
19. Wiholm BE. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. Curr Med Res Opin. 2001;17:210-216.
20. Gagnon R, Julien M, Gold P. Selective celecoxib associated anaphylactoid reaction. J Allergy Clin Immunol. 2003;111: 1404-1405.
21. Grob M, Pichler WJ, Wuthrich B. Anaphylaxis to celecoxib. Allergy. 2002;57:264-265.
22. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol. 2001;87:72-73.
23. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor [letter]. N Engl J Med. 2001;345: 1856.